CTKB Q3 2024 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CTKBCytek Biosciences, Inc.

$553M

Q3 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$52M+7.3% YoY

Gross Profit

$29M56.3% margin

Operating Income

-$4M-8.2% margin

Net Income

$941,0001.8% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+10.5%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$12M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$491M

Total Liabilities

$106M

Stockholders' Equity

$385M

Cash & Equivalents

$162M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$52M	$48M	+7.3%
Gross Profit	$29M	$27M	+6.7%
Operating Income	-$4M	-$6M	+33.8%
Net Income	$941,000	-$6M	+114.6%

Revenue Segments

Product

$40M50%

Service

$39M50%

Geographic Segments

UNITED STATES

$24M47%

EMEA

$17M33%

Asia Pacific

$9M17%

Other

$979,0002%